Antimicrobial chemotherapy undergoes a global crisis. The nineties brought the unprecedented spread of resistance
of main pathogenic bacteria to antibiotics, with an extent and intensity varying from negligible to threatening,
depending largely on the local or regional or nationwide approach to prescribing antibiotics. In some reqions the
microbial multiresistance led to various bacterial infections becoming untreatable, however, substantial increase of
costs of antibacterial chemotherapy - somewhere even prohibitive - has been felt everywhere, depending on the
necessity of using reserve drugs instead of basic ones. In he mid of nineties, the advent of a post-antibiotic era seemed
almost inevitable. Concentrated efforts aimed at rationalizing the antibiotic usage, at decreasing the useless
prescribing, at creating antibiotic policies as well as the development of new at the antibacterials have diminished
the danger, at least for some time. Brief descriptions of new drugs (linezolide, quinupristine/dalfoprostine, new
chinolones and naphythyridones and telithromycine) are given and some other, in the near future possibly useful
antibacterials (daptomycine, glycycyclines, oral carbapenems and trinems) are mentioned as well as some new ways
of antibacterial research. In a long-term view, however, rationalization of antibiotic prescribing is the only and
irreplaceable mean of maintaining the efficacy of antibacterial chemotherapy at acceptable costs.
antibiotics, antimicrobial chemotherapy, microbial multiresistance, pathogenic bacteria.